AR and prostate neoplasm: Studies using xenograft prostate tumors that recur following androgen ablation therapy show that although CRPC is insensitive to further androgen depletion treatment, the tissue still expresses AR regulated genes, suggesting that AR signaling pathways are still intact in CRPC [14, 15].